Next article Search Articles Instructions for authors  Access Statistics | Citation Manager  
ORIGINAL ARTICLE  

 Article Access Statistics
    Viewed3238    
    Printed94    
    Emailed0    
    PDF Downloaded280    
    Comments [Add]    

Recommend this journal

Methylene blue for postcardiopulmonary bypass vasoplegic syndrome: A cohort study


1 Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2 Department of Pharmacy, Children's National Medical Center, Washington, DC 20010, USA
3 Department of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA
4 Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
5 Department of Anesthesiology, University of California, San Francisco School of Medicine, San Francisco, CA 94131, USA
6 Department of Pharmacy, Emory University School of Medicine, Atlanta, GA 30322, USA

Correspondence Address:
Michael Mazzeffi
Department of Anesthesiology, University of Maryland School of Medicine, 22 South Greene Street S11C00, Baltimore, MD 21201
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aca.ACA_237_16

Rights and Permissions

Year : 2017  |  Volume : 20  |  Issue : 2  |  Page : 178-181

 

SEARCH
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles

  Article in PDF (564 KB)
Email article
Print Article
Add to My List
Background: Methylene blue (MB) has been used to treat refractory hypotension in a variety of settings. Aims: We sought to determine whether MB improved blood pressure in postcardiopulmonary bypass (CPB) vasoplegic syndrome (VS) in a complex cardiac surgery population. Furthermore, to determine variables that predicted response to MB. Setting and Design: This was conducted in a tertiary care medical center; this study was a retrospective cohort study. Materials and Methods: Adult cardiac surgery patients who received MB for post-CPB VS over a 2-year period were studied. Mean arterial blood pressure (MAP) and vasopressor doses were compared before and after MB, and logistic regression was used to model which variables predicted response. Results: Eighty-eight patients received MB for post-CPB VS during the study period. MB administration was associated with an 8 mmHg increase in MAP (P = 0.004), and peak response occurred at 2 h. Variables that were associated with a positive drug response were deep hypothermic circulatory arrest during surgery and higher MAP at the time of drug administration (P = 0.006 and 0.02). A positive response had no correlation with in-hospital mortality (P = 0.09). Conclusions: MB modestly increases MAP in cardiac surgery patients with VS. Higher MAP at the time of drug administration and surgery with deep hypothermic circulatory arrest predict a greater drug response.






[FULL TEXT] [PDF]*
 

 

 

 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 
 
 Reader Comments
 Email Alert *
  *
 * Requires registration (Free)
 
 ORIGINAL ARTICLE
 




1 Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2 Department of Pharmacy, Children's National Medical Center, Washington, DC 20010, USA
3 Department of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA
4 Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
5 Department of Anesthesiology, University of California, San Francisco School of Medicine, San Francisco, CA 94131, USA
6 Department of Pharmacy, Emory University School of Medicine, Atlanta, GA 30322, USA

Correspondence Address:
Michael Mazzeffi
Department of Anesthesiology, University of Maryland School of Medicine, 22 South Greene Street S11C00, Baltimore, MD 21201
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aca.ACA_237_16

Rights and Permissions

Background: Methylene blue (MB) has been used to treat refractory hypotension in a variety of settings. Aims: We sought to determine whether MB improved blood pressure in postcardiopulmonary bypass (CPB) vasoplegic syndrome (VS) in a complex cardiac surgery population. Furthermore, to determine variables that predicted response to MB. Setting and Design: This was conducted in a tertiary care medical center; this study was a retrospective cohort study. Materials and Methods: Adult cardiac surgery patients who received MB for post-CPB VS over a 2-year period were studied. Mean arterial blood pressure (MAP) and vasopressor doses were compared before and after MB, and logistic regression was used to model which variables predicted response. Results: Eighty-eight patients received MB for post-CPB VS during the study period. MB administration was associated with an 8 mmHg increase in MAP (P = 0.004), and peak response occurred at 2 h. Variables that were associated with a positive drug response were deep hypothermic circulatory arrest during surgery and higher MAP at the time of drug administration (P = 0.006 and 0.02). A positive response had no correlation with in-hospital mortality (P = 0.09). Conclusions: MB modestly increases MAP in cardiac surgery patients with VS. Higher MAP at the time of drug administration and surgery with deep hypothermic circulatory arrest predict a greater drug response.






[FULL TEXT] [PDF]*


        
Print this article     Email this article